Search company, investor...
ERYtech Pharma company logo

ERYtech Pharma

Founded Year




Total Raised


Date of IPO


Market Cap


About ERYtech Pharma

ERYtech Pharma is a French biotechnology company specialized in the encapsulation of therapeutic molecules or enzymes into red blood cells. ERYtech Pharma aims to offer therapeutic solutions that harness the physiological properties of red blood cells to improve the therapeutic index of the encapsulated molecules or enzymes.

Headquarters Location

60 ave Rockefeller

Lyon, 69008,



Missing: ERYtech Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ERYtech Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ERYtech Pharma Patents

ERYtech Pharma has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Transcription factors
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Pyridoxal phosphate enzymes, B vitamins, EC 2.6.1, Cofactors, Proteinogenic amino acids


Application Date


Grant Date



Related Topics

Pyridoxal phosphate enzymes, B vitamins, EC 2.6.1, Cofactors, Proteinogenic amino acids



Latest ERYtech Pharma News

Erytech says it is halting its lead Graspa program

Nov 22, 2022

Franco-American biopharma Erytech Pharma (Nasdaq: ERYP) revealed Monday that the company will no longer be developing its lead candidate Graspa (eryaspase), an l-asparaginase encapsulated inside donor-derived red blood cells (RBCs). Market reaction was sanguine, with the company’s shares closing up 1.6% at $0.65. The decision follows an earlier disappointment with the drug, when Erytech stopped further plans to pursue a Biologics License Application… This article is accessible to registered users, to continue reading please register for free . A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please  login . If your trial has come to an end, you can  subscribe here. • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. • Daily roundup of key events in pharma and biotech. • Monthly in-depth briefings on Boardroom appointments and M&A news. • Choose from a cost-effective annual package or a flexible monthly subscription. If you are already a registered user please login . The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed Chairman, Sanofi Aventis UK

ERYtech Pharma Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

ERYtech Pharma Rank

ERYtech Pharma Frequently Asked Questions (FAQ)

  • When was ERYtech Pharma founded?

    ERYtech Pharma was founded in 2004.

  • Where is ERYtech Pharma's headquarters?

    ERYtech Pharma's headquarters is located at 60 ave Rockefeller, Lyon.

  • What is ERYtech Pharma's latest funding round?

    ERYtech Pharma's latest funding round is IPO.

  • How much did ERYtech Pharma raise?

    ERYtech Pharma raised a total of $26.2M.

  • Who are the investors of ERYtech Pharma?

    Investors of ERYtech Pharma include OSEO, Amorcage Rhone-Alpes, Karista, AGF Private Equity, Auriga and 4 more.

  • Who are ERYtech Pharma's competitors?

    Competitors of ERYtech Pharma include Carmine Therapeutics, Vitatex, Advanced Analytical Technologies, Cellerant Therapeutics, REGiMMUNE and 13 more.

Compare ERYtech Pharma to Competitors

NKT Therapeutics

NKT Thereapeutics develops therapeutics based on a subset of immune cells called natural killer T cells.

Biosceptre International

Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs directed at the nf-P2X7 target have the potential to redefine cancer therapy. The Company has raised AUD33m and will be raising further capital through both existing and new investors. Biosceptre has a rigorous, international patent portfolio extending to 2032, providing broad protection of the target and specific protection of antibody products. The Company is developing therapeutics and diagnostics to bind nf-P2X7, with the core of product development in topical and systemic cancer drugs. Biosceptreis also developing an immuno-oncology vaccine, through an existing collaboration, and is in discussions with developmental partners to develop diagnostic and imaging technologies to detect and monitor cancer. Biosceptre is supported by a world-class scientific advisory board, the members of which have been central in the development of numerous, highly successful, biotechnology companies and products. The Company has the team, capital, and plan to create substantial value from this unique, patent-protected, technology. The business is headquartered in Cambridge, UK with additional research facilities in Sydney, Australia.


Abraxis BioScience is a biotechnology company dedicated to delivering progressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. The Abraxis portfolio includes the protein-based nanoparticle chemotherapeutic compound (ABRAXANE) which is based on its tumor targeting system known as the nab' Technology platform.

Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

Pi Proteomics

Pi Proteomics LLC manufactures custom and catalog peptides for academia, the biotechnology industry, antibody companies and the pharma industry.

American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.